{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:28:25Z","timestamp":1792787305682,"version":"4.5.0"},"reference-count":42,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T00:00:00Z","timestamp":1758499200000},"content-version":"unspecified","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2023M730374"],"award-info":[{"award-number":["2023M730374"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2024M750279"],"award-info":[{"award-number":["2024M750279"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20240342"],"award-info":[{"award-number":["BK20240342"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Clinical Frontier Technology Project of the Jiangsu Key Research and Development","award":["BE2022719"],"award-info":[{"award-number":["BE2022719"]}]},{"name":"Provincial-level Talent Program for National Center of Technology Innovation for Biopharmaceuticals","award":["NCTIB2024JS0101"],"award-info":[{"award-number":["NCTIB2024JS0101"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation Program of China","doi-asserted-by":"crossref","award":["32270955"],"award-info":[{"award-number":["32270955"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation Program of China","doi-asserted-by":"crossref","award":["81972869"],"award-info":[{"award-number":["81972869"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation Program of China","doi-asserted-by":"crossref","award":["82303164"],"award-info":[{"award-number":["82303164"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation Program of China","doi-asserted-by":"crossref","award":["82403938"],"award-info":[{"award-number":["82403938"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Leading Innovative Talents of Changzhou","award":["CQ20220114"],"award-info":[{"award-number":["CQ20220114"]}]},{"name":"Leading Innovative Talents of Changzhou","award":["CQ20220129"],"award-info":[{"award-number":["CQ20220129"]}]},{"DOI":"10.13039\/501100010023","name":"Natural Science Research of Jiangsu Higher Education Institutions of China","doi-asserted-by":"crossref","award":["23KJB320018"],"award-info":[{"award-number":["23KJB320018"]}],"id":[{"id":"10.13039\/501100010023","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,8,27]]},"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hepatocellular carcinoma (HCC) is a prevalent malignancy and the third leading cause of cancer-related mortality worldwide. Immune checkpoint inhibitors (ICIs) have emerged as first-line therapies for advanced HCC, substantially improving clinical outcomes. However, resistance to ICIs remains a major therapeutic challenge. Lactylation, a recently identified post-translational modification, has been implicated in tumor progression, although its role in ICIs resistance in HCC remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Cytotoxicity assays, flow cytometry and orthotopic HCC mouse model were used to evaluate the effects of lactylation in remodeling the immune microenvironment. Chromatin immunoprecipitation sequencing and RNA sequencing were employed to identify lactylation-regulated gene profiles. Programmed cell death-ligand 1 (PD-L1) protein degradation was assayed by cycloheximide-chase analysis and ubiquitination assay. Interactions between major vault protein (MVP) and \u03b2-transducin repeat-containing protein (\u03b2-TrCP) were analyzed by co-immunoprecipitation experiments. Site-directed mutagenesis and truncation mutants were designed to determine binding sites of MVP-\u03b2-TrCP complex.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Elevated lactylation correlates with poor prognosis and ICIs resistance in patients with HCC. Inhibition of lactylation enhances CD8\n                      <jats:sup>+<\/jats:sup>\n                      T-cell infiltration and cytokine production. Multiomics analyses identify MVP as a lactylation-regulated factor that suppresses CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cell-mediated antitumor immunity. Elevated MVP expression is associated with resistance to checkpoint blockade therapy. Mechanistic studies reveal that histone lactylation-induced MVP upregulation stabilizes PD-L1 by preventing \u03b2-TrCP-mediated proteasomal degradation. Pharmacological inhibition of lactylation restores ICIs sensitivity in orthotopic HCC mouse models.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings demonstrate that histone lactylation promotes ICIs resistance via MVP-dependent PD-L1 stabilization. Therefore, targeting lactylation in combination with programmed cell death protein-1\/PD-L1 blockade offers a promising strategy to overcome immunotherapy resistance in HCC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jitc-2025-012230","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T04:55:17Z","timestamp":1758516917000},"page":"e012230","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":30,"title":["Lactylation-driven MVP upregulation boosts immunotherapy resistance by inhibiting PD-L1 degradation in hepatocellular carcinoma"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6647-6197","authenticated-orcid":false,"given":"Shuang","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Oncology, Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-3221-953X","authenticated-orcid":false,"given":"Yihui","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Urology, Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6388-7758","authenticated-orcid":false,"given":"Wenjian","family":"Liu","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6455-1774","authenticated-orcid":false,"given":"Xiaoyun","family":"Bu","sequence":"additional","affiliation":[{"name":"Department of Colorectal Surgery, Hunan Cancer Hospital, Changsha, Hunan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5566-1848","authenticated-orcid":false,"given":"Ruonan","family":"Shao","sequence":"additional","affiliation":[{"name":"Sun Yat-sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwei","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changping","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China"},{"name":"Department of Tumor Biological Treatment, Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3128-9762","authenticated-orcid":false,"given":"Jingting","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Tumor Biological Treatment, Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China"},{"name":"Institute of Cell Therapy, Soochow University, Suzhou, Jiangsu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,9,21]]},"reference":[{"key":"2026052108452482000_13.9.e012230.1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"2026052108452482000_13.9.e012230.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745"},{"key":"2026052108452482000_13.9.e012230.3","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00240-3"},{"key":"2026052108452482000_13.9.e012230.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00573-2"},{"key":"2026052108452482000_13.9.e012230.5","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-1059"},{"key":"2026052108452482000_13.9.e012230.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2022.01.007"},{"key":"2026052108452482000_13.9.e012230.7","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-0406-2"},{"key":"2026052108452482000_13.9.e012230.8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103627","article-title":"Lactate in the tumour microenvironment: From immune modulation to therapy","volume":"73","author":"Wang","year":"2021","journal-title":"EBioMedicine"},{"key":"2026052108452482000_13.9.e012230.9","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1678-1"},{"key":"2026052108452482000_13.9.e012230.10","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.688910","article-title":"Lactylation, a Novel Metabolic Reprogramming Code: Current Status and Prospects","volume":"12","author":"Chen","year":"2021","journal-title":"Front Immunol"},{"key":"2026052108452482000_13.9.e012230.11","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abi6696","article-title":"Class I histone deacetylases (HDAC1-3) are histone lysine delactylases","volume":"8","author":"Moreno-Yruela","year":"2022","journal-title":"Sci Adv"},{"key":"2026052108452482000_13.9.e012230.12","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s42255-022-00710-w","article-title":"Lactylome analysis suggests lactylation-dependent mechanisms of metabolic adaptation in hepatocellular carcinoma","volume":"5","author":"Yang","year":"2023","journal-title":"Nat Metab"},{"key":"2026052108452482000_13.9.e012230.13","doi-asserted-by":"crossref","DOI":"10.15252\/embr.202256052","article-title":"SIRT3-dependent delactylation of cyclin E2 prevents hepatocellular carcinoma growth","volume":"24","author":"Jin","year":"2023","journal-title":"EMBO Rep"},{"key":"2026052108452482000_13.9.e012230.14","doi-asserted-by":"crossref","first-page":"106270","DOI":"10.1016\/j.phrs.2022.106270","article-title":"Demethylzeylasteral targets lactate by inhibiting histone lactylation to suppress the tumorigenicity of liver cancer stem cells","volume":"181","author":"Pan","year":"2022","journal-title":"Pharmacol Res"},{"key":"2026052108452482000_13.9.e012230.15","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-008-8364-z"},{"key":"2026052108452482000_13.9.e012230.16","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1002\/jps.21508","article-title":"Structural stability of vault particles","volume":"98","author":"Esfandiary","year":"2009","journal-title":"J Pharm Sci"},{"key":"2026052108452482000_13.9.e012230.17","doi-asserted-by":"crossref","first-page":"416","DOI":"10.2183\/pjab.88.416","article-title":"Structural studies of large nucleoprotein particles, vaults","volume":"88","author":"Tanaka","year":"2012","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"key":"2026052108452482000_13.9.e012230.18","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M313955200"},{"key":"2026052108452482000_13.9.e012230.19","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.02773"},{"key":"2026052108452482000_13.9.e012230.20","doi-asserted-by":"publisher","DOI":"10.1126\/science.1142311"},{"key":"2026052108452482000_13.9.e012230.21","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-09588-x","article-title":"Major vault protein suppresses obesity and atherosclerosis through inhibiting IKK-NF-\u03baB signaling mediated inflammation","volume":"10","author":"Ben","year":"2019","journal-title":"Nat Commun"},{"key":"2026052108452482000_13.9.e012230.22","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206947"},{"key":"2026052108452482000_13.9.e012230.23","doi-asserted-by":"publisher","DOI":"10.1002\/hep.25642"},{"key":"2026052108452482000_13.9.e012230.24","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13040707","article-title":"The Vault Nanoparticle: A Gigantic Ribonucleoprotein Assembly Involved in Diverse Physiological and Pathological Phenomena and an Ideal Nanovector for Drug Delivery and Therapy","volume":"13","author":"Frascotti","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026052108452482000_13.9.e012230.25","doi-asserted-by":"publisher","DOI":"10.1016\/S1534-5807(03)00154-0"},{"key":"2026052108452482000_13.9.e012230.26","doi-asserted-by":"publisher","DOI":"10.1016\/S1534-5807(03)00153-9"},{"key":"2026052108452482000_13.9.e012230.27","doi-asserted-by":"publisher","DOI":"10.1126\/science.1164975"},{"key":"2026052108452482000_13.9.e012230.28","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-019-1870-5","article-title":"Epigenetic modifications of histones in cancer","volume":"20","author":"Zhao","year":"2019","journal-title":"Genome Biol"},{"key":"2026052108452482000_13.9.e012230.29","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/s41586-024-07620-9","article-title":"NBS1 lactylation is required for efficient DNA repair and chemotherapy resistance","volume":"631","author":"Chen","year":"2024","journal-title":"Nature New Biol"},{"key":"2026052108452482000_13.9.e012230.30","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1080\/15548627.2023.2249762","article-title":"Tumor-derived lactate promotes resistance to bevacizumab treatment by facilitating autophagy enhancer protein RUBCNL expression through histone H3 lysine 18 lactylation (H3K18la) in colorectal cancer","volume":"20","author":"Li","year":"2024","journal-title":"Autophagy"},{"key":"2026052108452482000_13.9.e012230.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101059"},{"key":"2026052108452482000_13.9.e012230.32","doi-asserted-by":"publisher","DOI":"10.1038\/nm0695-578"},{"key":"2026052108452482000_13.9.e012230.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2012.01.002"},{"key":"2026052108452482000_13.9.e012230.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.11.035"},{"key":"2026052108452482000_13.9.e012230.35","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1501481"},{"key":"2026052108452482000_13.9.e012230.36","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2012529118","article-title":"Immunoediting role for major vault protein in apoptotic signaling induced by bacterial N-acyl homoserine lactones","volume":"118","author":"Rayo","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026052108452482000_13.9.e012230.37","doi-asserted-by":"crossref","first-page":"154243","DOI":"10.1016\/j.prp.2022.154243","article-title":"Correlation of expression of Major Vault Protein with androgen receptor and immune checkpoint protein B7-H3, and with poor prognosis in prostate cancer","volume":"241","author":"Nunes-Xavier","year":"2023","journal-title":"Pathol Res Pract"},{"key":"2026052108452482000_13.9.e012230.38","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms14448","article-title":"MVP-mediated exosomal sorting of miR-193a promotes colon cancer progression","volume":"8","author":"Teng","year":"2017","journal-title":"Nat Commun"},{"key":"2026052108452482000_13.9.e012230.39","doi-asserted-by":"crossref","first-page":"216089","DOI":"10.1016\/j.canlet.2023.216089","article-title":"Extracellular vesicle RNA signaling in the liver tumor microenvironment","volume":"558","author":"Gondaliya","year":"2023","journal-title":"Cancer Lett"},{"key":"2026052108452482000_13.9.e012230.40","doi-asserted-by":"crossref","first-page":"1399222","DOI":"10.3389\/fimmu.2024.1399222","article-title":"Unraveling the role of Major Vault Protein as a novel immune-related biomarker that promotes the proliferation and migration in pancreatic adenocarcinoma","volume":"15","author":"Wu","year":"2024","journal-title":"Front Immunol"},{"key":"2026052108452482000_13.9.e012230.41","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2022.11.007"},{"key":"2026052108452482000_13.9.e012230.42","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.632364","article-title":"Inhibition of LDH-A by Oxamate Enhances the Efficacy of Anti-PD-1 Treatment in an NSCLC Humanized Mouse Model","volume":"11","author":"Qiao","year":"2021","journal-title":"Front Oncol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2025-012230","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:45:38Z","timestamp":1779378338000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2025-012230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":42,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,21]]},"published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1136\/jitc-2025-012230"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2025-012230","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]}}}